BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
Cancer research (Chicago, Ill.), 2004-10, Vol.64 (19), p.7099-7109 [Peer Reviewed Journal]2004 INIST-CNRS ;ISSN: 0008-5472 ;EISSN: 1538-7445 ;DOI: 10.1158/0008-5472.CAN-04-1443 ;PMID: 15466206 ;CODEN: CNREA8
Full text available